PRX003 is a monoclonal antibody under development by Prothena for the possible treatment of inflammatory diseases. It is currently being tested in patients with multiple sclerosis (MS).

Immune cells release cytokines that can trigger inflammation and are central to many inflammatory diseases. An MCAM (melanoma cell adhesion molecule) binds to a partner molecule the blood stream then then allows it to infiltrate adjacent tissues, leading to inflammation.

In healthy people, the blood-brain barrier prevents immune cells (lymphocytes) from entering the central nervous system. In people with MS, two types of lymphocytes, CD4 and CD8, find a way to cross the barrier. They then destroy the myelin sheath that protects neurons, resulting in brain lesions.

MCAM may play a crucial role in MS because it is necessary for the migration of both CD4 and CD8 lymphocytes across the blood-brain barrier. Blocking MCAM may delay the onset of MS and significantly slow its progression.

PRX003 binds to MCAM, blocks the route of inflammation, and prevents the migration of CD4 and CD8 lymphocytes into the brain tissue.

In March, Prothena completed a single ascending dose study of PRX003 in healthy participants (NCT02458677). All doses of PRX003 were reported as safe and tolerated following a single infusion up to 30 mg/kg dose. The results showed that PRX003 administration led to more than 95 percent MCAM neutralization.

Adverse effects reported were headache, balance disorder, seasonal allergies, and viral upper respiratory tract infection in 5 percent of participants.

A Phase 1b clinical study of PRX003 in people with psoriasis (NCT02630901) is ongoing.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Fewer Pregnancies, Premature Menopause Linked to Early Onset of Progressive MS

Women who have never given birth are more likely to develop early onset of progressive multiple sclerosis, according to a new study, which also found that a woman’s number of pregnancies showed a positive effect in delaying the disease. In addition, entering menopause earlier, before the age of 46, is linked with earlier onset of […]

MS News That Caught My Eye Last Week: More Tysabri Benefits, Long-term Ocrevus Data, Trial Diversity, MS and the Gut

Tysabri Affects Immune System Beyond Known MS Target, Study Finds Tysabri (natalizumab) slows multiple sclerosis progression by blocking some immune cells from entering the central nervous system, where they attack the myelin coating of nerves. Yet this study shows that Tysabri may also significantly reduce the number of proteins in the blood that trigger inflammatory […]

Novartis, iHeartRadio Partner to Launch 1st Streaming Station for MS Community

Novartis has partnered with iHeartRadio to launch the first free on-demand streaming radio station dedicated to the multiple sclerosis (MS) community. Named MS Vibes, the station is focused “on popular music, educational content and relatable topics to which listeners can connect, uplift and recharge,” Leverne Marsh, vice president and head of Novartis’ U.S. neuroscience franchise, said in […]

How important is it to start treatment for relapsing MS? Sponsored Post

The short answer is: You should start treating relapsing multiple sclerosis (MS) as soon as possible after you are diagnosed. Research has shown that this is the best way to slow disease progression.1 With many disease-modifying treatments (DMTs) on the market,2 narrowing down what is important in your journey early on with your healthcare provider […]

New $100M Program Aims to Improve Diversity in Clinical Trials

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient populations. The initiative seeks to extend the reach of clinical studies to underserved populations in the nation’s urban and rural communities, and promote treatment development […]

Tablet-based Video Game Could Help Measure Cognitive Impairment in MS, Study Shows

People with multiple sclerosis (MS) may have cognitive defects that cannot be detected using conventional paper-and-pen tests but that can be assessed with computer-based tests, a new study shows. The findings also indicate that people with MS may be more susceptible to cognitive impairment when the brain has to address increased task demands. The study, “Visual-Attentional […]

Gut Immune Cells That Travel to Brain May Help Resolve MS Disease Relapses

A particular type of gut microbiota-reactive immune cells, called IgA-producing B-cells, travels to the brain of multiple sclerosis (MS) patients during relapses, where they produce anti-inflammatory molecules, a study shows. The underlying mechanisms of this event and these cells’ role in MS remain largely unclear, but these findings suggest that specific gut immune cells may […]

How Lucy the Dog Changed My Life

A pet is the most loyal companion a person can have.  I’m currently sitting in my dad’s home office and typing away on my laptop. It’s nice to have a change of scenery. I brought my tiny dog, Lucy, with me as usual. Lucy is more than my dog. She’s my shadow, and she never, […]

Tysabri Affects Immune System Beyond Known MS Target, Study Finds

Lower levels of pro-inflammatory immune signaling proteins were found in the blood of people with relapsing-remitting multiple sclerosis (RRMS) treated with Tysabri (natalizumab) and were associated with fewer relapses and less disability, a study has found. The findings show Tysabri affects the immune system beyond its known target and support the use of the immune […]